Key Takeaways:
- Revenue rose 8.3% to €1.48 billion in the first half of 2026.
- EBITDA margin of 30.3% edged past the Vara consensus of 30%.
- The Bioprocess Solutions division, representing 80% of sales, drove results.
Atrás
Sartorius beats H1 earnings estimates as tariff refunds boost margins
Sartorius reported first-half revenue of €1.48 billion, with an EBITDA margin of 30.3% that beat consensus estimates.
"The timing and amount of the US tariff refunds had long been uncertain, so it is good to have more clarity now," CEO Michael Grosse said in a statement.
Revenue grew 8.3% in constant currencies from a year earlier, the German biopharma supplier said Thursday. The Bioprocess Solutions division, which supplies technologies used to manufacture biopharmaceuticals and accounts for about 80% of group sales, was the primary growth driver. The company confirmed its full-year guidance.
The earnings beat signals that Sartorius is navigating a challenging macro environment, with stable recurring business and US tariff refunds providing a tailwind. Investors will watch for further updates on customer engagements regarding refunded surcharges, which Grosse said the company is currently addressing.
Sartorius, which trades on the Frankfurt Stock Exchange, reported sales of €1.48 billion ($1.69 billion) for the first six months of 2026. The underlying earnings margin before interest, taxes, depreciation and amortization came in at 30.3%, just above the 30% consensus compiled by Vara.
The company's Bioprocess Solutions division supplies single-use technologies, filtration systems and fermentation equipment to drugmakers. The division's performance reflects steady demand from pharmaceutical customers for biologics manufacturing supplies.
Grosse added that Sartorius is engaging with customers on refunding previously paid surcharges related to US tariffs, which had a non-operating effect on reported results.
The guidance confirmation suggests management sees sustained demand for bioprocessing equipment through the remainder of 2026. Investors will watch the company's third-quarter trading update for further clarity on margin trajectory and tariff-related impacts.
This article is for informational purposes only and does not constitute investment advice.
[1] Sartorius beats half-year earnings expectations[2] Tesla misses on earnings, as free cash flow turns negative and margins slide[3] Otis Worldwide Corporation (OTIS) Q2 2026 Earnings Call Transcript[4] Otis forecasts 2026 adjusted EPS $4.01-$4.05 while targeting $15.1B-$15.3B sales amid service cost headwinds
Características
© 2026 Edgen impulsado por